Munich - Delayed Quote EUR
Revive Therapeutics Ltd (31R.MU)
0.0180
0.0000
(0.00%)
At close: April 25 at 8:04:35 AM GMT+2
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Expense
2,922.2800
3,286.0440
5,521.0130
17,833.0260
18,592.4540
Operating Income
-2,922.2800
-3,286.0440
-5,521.0130
-17,833.0260
-18,592.4540
Net Non Operating Interest Income Expense
2.9720
38.6900
64.6130
52.8000
17.7520
Other Income Expense
--
-2,371.2680
-864.5000
-26.7010
-1,544.1000
Pretax Income
-5,294.5960
-5,618.6220
-6,320.9000
-17,806.9270
-20,118.8020
Net Income Common Stockholders
-5,294.5960
-5,618.6220
-6,320.9000
-17,806.9270
-20,118.8020
Diluted NI Available to Com Stockholders
-5,294.5960
-5,618.6220
-6,320.9000
-17,806.9270
-20,118.8020
Basic EPS
-0.01
-0.01
-0.02
-0.06
-0.08
Diluted EPS
-0.01
-0.01
-0.02
-0.06
-0.08
Basic Average Shares
410,898.3560
380,483.1210
339,370.6350
319,763.9660
267,491.0890
Diluted Average Shares
410,898.3560
380,483.1210
339,370.6350
319,763.9660
267,491.0890
Total Expenses
2,922.2800
3,286.0440
5,521.0130
17,833.0260
18,592.4540
Net Income from Continuing & Discontinued Operation
-5,294.5960
-5,618.6220
-6,320.9000
-17,806.9270
-20,118.8020
Normalized Income
-2,919.3080
-3,247.3540
-5,456.4000
-17,780.2260
-18,574.7020
Interest Income
12.4200
61.9780
112.7850
123.1630
103.0790
Interest Expense
7.3420
20.0950
43.9970
63.4230
78.9820
Net Interest Income
2.9720
38.6900
64.6130
52.8000
17.7520
EBIT
-5,287.2540
-5,598.5270
-6,276.9030
-17,743.5040
-20,039.8200
EBITDA
-5,286.9660
-5,598.1990
-6,276.4690
-17,742.9260
-20,039.0450
Reconciled Depreciation
0.2880
0.3280
0.4340
0.5780
0.7750
Net Income from Continuing Operation Net Minority Interest
-5,294.5960
-5,618.6220
-6,320.9000
-17,806.9270
-20,118.8020
Total Unusual Items Excluding Goodwill
-2,375.2880
-2,371.2680
-864.5000
-26.7010
-1,544.1000
Total Unusual Items
-2,375.2880
-2,371.2680
-864.5000
-26.7010
-1,544.1000
Normalized EBITDA
-2,911.6780
-3,226.9310
-5,411.9690
-17,716.2250
-18,494.9450
6/30/2021 - 4/6/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade